MX2016001361A - Compuestos terapeuticamente activos y sus metodos de uso. - Google Patents
Compuestos terapeuticamente activos y sus metodos de uso.Info
- Publication number
- MX2016001361A MX2016001361A MX2016001361A MX2016001361A MX2016001361A MX 2016001361 A MX2016001361 A MX 2016001361A MX 2016001361 A MX2016001361 A MX 2016001361A MX 2016001361 A MX2016001361 A MX 2016001361A MX 2016001361 A MX2016001361 A MX 2016001361A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- active compounds
- therapeutically active
- idh2
- treating cancer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 abstract 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan compuestos inhibidores de isocitrato deshidrogenasa 2 (IDH2) útiles para tratar cáncer y métodos para tratar cáncer, que comprenden administrar a un sujeto en necesidad del mismo, un compuesto descrito en la presente. También se proporcionan formas polimórficas de los compuestos inhibidores de IDH2 caracterizadas por patrones de difracción en polvo por Rayos X, que tienen propiedades fisicoquímicas mejoradas que influyen la tasa de disolución in vivo para propósitos de formulación.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361861884P | 2013-08-02 | 2013-08-02 | |
| PCT/CN2013/081170 WO2015018060A1 (en) | 2013-08-09 | 2013-08-09 | Crystalline forms of therapeutically active compounds and use thereof |
| US201461939098P | 2014-02-12 | 2014-02-12 | |
| US201461975448P | 2014-04-04 | 2014-04-04 | |
| US201462011948P | 2014-06-13 | 2014-06-13 | |
| PCT/US2014/049469 WO2015017821A2 (en) | 2013-08-02 | 2014-08-01 | Therapeutically active compounds and their methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016001361A true MX2016001361A (es) | 2016-06-14 |
| MX389250B MX389250B (es) | 2025-03-20 |
Family
ID=52432592
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011397A MX394658B (es) | 2013-08-02 | 2014-08-01 | Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos |
| MX2016001361A MX389250B (es) | 2013-08-02 | 2014-08-01 | Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011397A MX394658B (es) | 2013-08-02 | 2014-08-01 | Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9738625B2 (es) |
| EP (3) | EP3027193A4 (es) |
| JP (3) | JP6742905B2 (es) |
| CN (3) | CN105916507A (es) |
| AU (2) | AU2014295938B2 (es) |
| BR (1) | BR112016002287A2 (es) |
| CA (1) | CA2919382A1 (es) |
| CL (2) | CL2016000263A1 (es) |
| EA (1) | EA030428B1 (es) |
| ES (1) | ES2886211T3 (es) |
| IL (2) | IL243833A0 (es) |
| MX (2) | MX394658B (es) |
| MY (1) | MY177994A (es) |
| NI (1) | NI201600022A (es) |
| PE (1) | PE20160840A1 (es) |
| PH (1) | PH12016500164B1 (es) |
| SA (1) | SA516370523B1 (es) |
| SG (2) | SG10201709187TA (es) |
| TW (2) | TWI701242B (es) |
| UA (1) | UA121021C2 (es) |
| WO (1) | WO2015017821A2 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| TWI701242B (zh) * | 2013-08-02 | 2020-08-11 | 美商阿吉斯藥品股份有限公司 | 治療活性化合物及其使用方法(三) |
| WO2016053850A1 (en) | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3253746A1 (en) | 2015-02-04 | 2017-12-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2016177347A1 (en) * | 2015-05-07 | 2016-11-10 | Teligene Ltd | Heterocyclic compounds as idh2 inhibitors |
| TWI722004B (zh) * | 2015-07-30 | 2021-03-21 | 大陸商正大天晴藥業集團股份有限公司 | 1,3,5-三嗪衍生物及其使用方法 |
| CN108349933A (zh) | 2015-08-05 | 2018-07-31 | 安吉奥斯医药品有限公司 | 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法 |
| KR20250065944A (ko) | 2015-10-15 | 2025-05-13 | 르 라보레또레 쎄르비에르 | 악성종양을 치료하기 위한 복합 요법 |
| SG10201912869WA (en) | 2015-10-15 | 2020-02-27 | Celgene Corp | Combination therapy for treating malignancies |
| WO2017069878A1 (en) * | 2015-10-21 | 2017-04-27 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof |
| US20200268726A1 (en) * | 2015-12-04 | 2020-08-27 | Agios Pharmaceuticals, Inc. | Methods of treatment of malignancies |
| WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
| KR20180114202A (ko) | 2016-02-26 | 2018-10-17 | 아지오스 파마슈티컬스 아이엔씨. | 혈액 악성종양 및 고형 종양의 치료를 위한 idh1 억제제 |
| JP7093764B2 (ja) * | 2016-08-03 | 2022-06-30 | セルジーン コーポレイション | 骨髄異形成症候群の治療方法 |
| WO2018026894A1 (en) | 2016-08-03 | 2018-02-08 | Celgene Corporation | Methods of treatment of myelodysplastic syndrome |
| CA3036053A1 (en) * | 2016-09-07 | 2018-03-15 | Celgene Corporation | Tablet compositions |
| JP7111725B2 (ja) * | 2017-01-22 | 2022-08-02 | 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 | １，３，５－トリアジン誘導体の塩およびその結晶、その製造方法、医薬組成物、ならびにそれらの使用 |
| ES2968376T3 (es) | 2017-05-05 | 2024-05-09 | Memorial Sloan Kettering Cancer Center | Métodos de tratamiento de neoplasia mieloproliferativa |
| SG11201913008TA (en) | 2017-06-30 | 2020-01-30 | Celgene Corp | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-doxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2021097160A1 (en) | 2019-11-14 | 2021-05-20 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| CN114773320A (zh) * | 2022-05-29 | 2022-07-22 | 重庆医科大学 | 1,3,5-三嗪化合物及其制备方法和用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390529A (en) | 1942-02-03 | 1945-12-11 | Ernst A H Friedheim | Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds |
| JPS58186682A (ja) | 1982-04-27 | 1983-10-31 | 日本化薬株式会社 | セルロ−ス又はセルロ−ス含有繊維材料の染色法 |
| DE3512630A1 (de) | 1985-04-06 | 1986-10-23 | Hoechst Ag, 6230 Frankfurt | Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern |
| EP0466647B1 (de) | 1990-07-12 | 1995-11-29 | Ciba-Geigy Ag | Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| EP1187825A1 (en) | 1999-06-07 | 2002-03-20 | Shire Biochem Inc. | Thiophene integrin inhibitors |
| US7291616B2 (en) * | 2001-10-31 | 2007-11-06 | Cell Therapeutics, Inc. | Aryl triazines as LPAAT-β inhibitors and uses thereof |
| WO2004009562A1 (en) | 2002-07-18 | 2004-01-29 | Janssen Pharmaceutica, Nv | Substituted triazine kinase inhibitors |
| CA2684968C (en) * | 2007-04-30 | 2015-07-07 | Prometic Biosciences Inc. | Compounds, compositions containing such compounds, and methods of treatment of cancer and autoimmune diseases using such compounds |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| EP2440050A4 (en) * | 2009-06-08 | 2013-04-03 | California Capital Equity Llc | TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION |
| EP2532659A1 (en) * | 2009-07-07 | 2012-12-12 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| RS57401B1 (sr) * | 2012-01-06 | 2018-09-28 | Agios Pharmaceuticals Inc | Terapeutski aktivna jedinjenja i postupci za njihovu upotrebu |
| WO2013133367A1 (ja) | 2012-03-09 | 2013-09-12 | カルナバイオサイエンス株式会社 | 新規トリアジン誘導体 |
| JP6471155B2 (ja) | 2013-07-11 | 2019-02-13 | アギオス ファーマシューティカルス，インコーポレーテッド | 癌の治療のためのｉｄｈ２変異体阻害剤としてのｎ，６−ビス（アリール又はヘテロアリール）−１，３，５−トリアジン−２，４−ジアミン化合物 |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| TWI701242B (zh) * | 2013-08-02 | 2020-08-11 | 美商阿吉斯藥品股份有限公司 | 治療活性化合物及其使用方法(三) |
| WO2016053850A1 (en) | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3253746A1 (en) | 2015-02-04 | 2017-12-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
-
2014
- 2014-08-01 TW TW108110624A patent/TWI701242B/zh active
- 2014-08-01 CN CN201480053796.5A patent/CN105916507A/zh active Pending
- 2014-08-01 US US14/909,451 patent/US9738625B2/en active Active
- 2014-08-01 BR BR112016002287A patent/BR112016002287A2/pt not_active Application Discontinuation
- 2014-08-01 PE PE2016000214A patent/PE20160840A1/es not_active Application Discontinuation
- 2014-08-01 CN CN201910708167.6A patent/CN110386922A/zh active Pending
- 2014-08-01 CN CN201910707312.9A patent/CN110372670B/zh active Active
- 2014-08-01 SG SG10201709187TA patent/SG10201709187TA/en unknown
- 2014-08-01 AU AU2014295938A patent/AU2014295938B2/en active Active
- 2014-08-01 UA UAA201601999A patent/UA121021C2/uk unknown
- 2014-08-01 MY MYPI2016700311A patent/MY177994A/en unknown
- 2014-08-01 WO PCT/US2014/049469 patent/WO2015017821A2/en not_active Ceased
- 2014-08-01 MX MX2020011397A patent/MX394658B/es unknown
- 2014-08-01 CA CA2919382A patent/CA2919382A1/en not_active Abandoned
- 2014-08-01 EP EP14832505.3A patent/EP3027193A4/en not_active Withdrawn
- 2014-08-01 PH PH1/2016/500164A patent/PH12016500164B1/en unknown
- 2014-08-01 EP EP19177845.5A patent/EP3566706B1/en active Active
- 2014-08-01 TW TW103126335A patent/TWI666208B/zh active
- 2014-08-01 ES ES19177845T patent/ES2886211T3/es active Active
- 2014-08-01 MX MX2016001361A patent/MX389250B/es unknown
- 2014-08-01 JP JP2016531940A patent/JP6742905B2/ja active Active
- 2014-08-01 EA EA201690322A patent/EA030428B1/ru not_active IP Right Cessation
- 2014-08-01 EP EP21178745.2A patent/EP3932408A1/en not_active Withdrawn
- 2014-08-01 SG SG11201600479WA patent/SG11201600479WA/en unknown
-
2016
- 2016-01-28 IL IL243833A patent/IL243833A0/en unknown
- 2016-02-01 NI NI201600022A patent/NI201600022A/es unknown
- 2016-02-01 SA SA516370523A patent/SA516370523B1/ar unknown
- 2016-02-02 CL CL2016000263A patent/CL2016000263A1/es unknown
-
2017
- 2017-07-13 US US15/649,551 patent/US10093654B2/en active Active
- 2017-09-04 CL CL2017002240A patent/CL2017002240A1/es unknown
-
2018
- 2018-09-04 US US16/121,483 patent/US10730854B2/en active Active
- 2018-10-10 AU AU2018247242A patent/AU2018247242B2/en active Active
-
2019
- 2019-04-24 JP JP2019082794A patent/JP2019142930A/ja not_active Withdrawn
- 2019-10-31 IL IL270347A patent/IL270347B/en unknown
-
2020
- 2020-06-29 US US16/915,936 patent/US20210155603A1/en not_active Abandoned
-
2021
- 2021-07-29 JP JP2021123814A patent/JP2021176893A/ja active Pending
-
2023
- 2023-05-08 US US18/144,695 patent/US20240132474A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011397A (es) | Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos. | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| MX2016011810A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| BR112015022047A8 (pt) | uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| NI201500094A (es) | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos. | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| NI201500096A (es) | Compuesto químicos | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| AR096402A1 (es) | Medicamento de metformina y dihidroquercetina | |
| BR112015027477A2 (pt) | método para tratamento de um transtorno de deglutição | |
| UY34076A (es) | Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra tumores sólidos avanzados | |
| PH12017502046A1 (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| AR097890A1 (es) | Compuestos de urea | |
| HK1224582A1 (en) | Therapeutically active compounds and their methods of use | |
| CR20160054A (es) | Compuestos terapeuticamente activos y sus métodos de uso |